Achieving target voriconazole concentrations more accurately in children and adolescents

Antimicrobial Agents and Chemotherapy
Michael NeelyWilliam Hope

Abstract

Despite the documented benefit of voriconazole therapeutic drug monitoring, nonlinear pharmacokinetics make the timing of steady-state trough sampling and appropriate dose adjustments unpredictable by conventional methods. We developed a nonparametric population model with data from 141 previously richly sampled children and adults. We then used it in our multiple-model Bayesian adaptive control algorithm to predict measured concentrations and doses in a separate cohort of 33 pediatric patients aged 8 months to 17 years who were receiving voriconazole and enrolled in a pharmacokinetic study. Using all available samples to estimate the individual Bayesian posterior parameter values, the median percent prediction bias relative to a measured target trough concentration in the patients was 1.1% (interquartile range, -17.1 to 10%). Compared to the actual dose that resulted in the target concentration, the percent bias of the predicted dose was -0.7% (interquartile range, -7 to 20%). Using only trough concentrations to generate the Bayesian posterior parameter values, the target bias was 6.4% (interquartile range, -1.4 to 14.7%; P = 0.16 versus the full posterior parameter value) and the dose bias was -6.7% (interquartile range, -18....Continue Reading

Citations

Nov 6, 2015·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Karin KatoSatoshi Ichiyama
Mar 17, 2016·Clinical Pharmacokinetics·Rajendra S Kadam, Johannes N Van Den Anker
Mar 25, 2016·The Journal of Antimicrobial Chemotherapy·Alison BoastAmanda Gwee
Mar 17, 2016·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoMichael Neely
Apr 29, 2016·The Journal of Antimicrobial Chemotherapy·William W HopeUNKNOWN Blood and Marrow Transplant Clinical Trials Network
Jun 30, 2016·Expert Review of Anti-infective Therapy·Kathleen M JobCatherine M T Sherwin
Dec 3, 2016·Journal of Pharmacokinetics and Pharmacodynamics·David S Bayard, Michael Neely
Dec 17, 2016·Clinical Pharmacology and Therapeutics·M Neely
Mar 8, 2017·The Journal of Pharmacy and Pharmacology·Basma Al-Metwali, Hussain Mulla
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·Silke GastineGeorg Hempel
Aug 2, 2017·Antimicrobial Agents and Chemotherapy·V Ramos-MartínW W Hope
Feb 3, 2016·Antimicrobial Agents and Chemotherapy·Luc J HuurnemanWilliam Hope
Oct 5, 2016·Antimicrobial Agents and Chemotherapy·Cinzia AuritiManjunath P Pai
Aug 29, 2018·Antimicrobial Agents and Chemotherapy·Lin HuTao Yin
Jan 24, 2019·Antimicrobial Agents and Chemotherapy·William HopeMichael Neely
Jan 29, 2019·Mycoses·Fabianne Altruda de Moraes Costa CarlesseAntonio Sergio Petrilli
Sep 7, 2017·Clinical and Translational Science·Daniel GonzalezJ Robert Powell
Sep 19, 2019·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Sin Yin Lim, Rebecca S Pettit
Jun 5, 2020·British Journal of Clinical Pharmacology·Luqman ValiHussain Mulla
Jan 29, 2019·Clinical Pharmacokinetics·Changcheng ShiNengming Lin
Oct 10, 2020·Annual Review of Pharmacology and Toxicology·Adam S DarwichAmin Rostami-Hodjegan
May 19, 2021·Clinical Pharmacokinetics·Didi BuryRoger J Brüggemann
Jun 30, 2021·Journal of Clinical Pharmacology·Jeffrey S BarrettAlexander A Vinks
May 20, 2021·Current Opinion in Infectious Diseases·Russell E Lewis, David R Andes
Jun 22, 2021·Antimicrobial Agents and Chemotherapy·Jun WangYang Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.